Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A Mendelian randomization cytokine screen reveals IL-13 as a causal factor in risk of severe COVID-19

We read a recent paper by Li and colleagues with interest, who reported association of genetic polymorphisms in IFTM3 with COVID-19 susceptibility and severity with implicated conclusions for vaccination or therapeutic goals. In the current study we leveraged the previously discovered association of single-nucleotide polymorphisms (SNPs) for circulating cytokine levels to investigate their causal role in severe COVID-19. To this end, we used the promising methodology of Mendelian randomization (MR) to infer potential causality of risk factor-disease associations. This method uses genetic variants as instrumental variables to test for the effect of exposures on outcomes while minimizing confounding bias. We selected a recently introduced, powerful MR approach, i.e., Generalized Summary-data-based MR (GSMR), to detect any potentially causal links between baseline blood cytokine levels and severe COVID-19 disease. We then confirmed the observed links with MR sensitivity analyses and also validated the findings using replication in three independent datasets: 1) replication in an independent East Asian GWAS for severe COVID-19, 2) internal replication using subsets of the discovery GWAS for severe COVID-19, and 3) replication at transcript level using an independent set of SNPs as instrumental variables. Subsequently, for any cytokine showing a significant effect on severe COVID-19 we performed MR analyses with other cytokine levels as outcomes, to examine their regulatory role.

Our study is based on the GWAS results of 4336 very severe COVID-19 cases and 623,902 controls (Supplementary Table 1), conducted by the Host Genetics Initiative consortium with severe COVID-19 disease (or death due to COVID-19) as the outcome. For the exposures, we used GWAS results of 41 cytokines and growth factors from an independent population of 8293 individuals. For independent replication, we used GWAS results of 65 East Asian severe COVID-19 cases versus 138 ancestry-matched controls and for replication at transcript level, we used expression quantitative trait loci data from blood T cells by Chen et al. Detailed description of the data and methods is given in Supplementary Materials.

We were able to test 13 cytokines having at least 3 independent SNPs for GSMR of which our analyses suggested a causal role for IL-13 in severe COVID-19 with each standard deviation (SD) increase in plasma levels of IL-13 leading to about 20% higher odds of developing severe COVID-19 (OR [CI 95%]=1.23 [1.05–1.44], \( P = 0.0087 \)) (Table 1 and Fig. 1A). The full results of all tested cytokines are represented in Supplementary Table 2.

Leave-one-SNP-out sensitivity analysis showed that none of the SNPs used is driving the association. However, in one case, i.e., when excluding rs9472168, the association becomes stronger (OR [CI 95%] = 1.51 [1.09–2.10]; per standard deviation increase in IL-13 levels) (Fig. 1B). This could be an influential, potentially pleiotropic SNP, the inclusion of which may have resulted in underestimation of the MR effect. Reverse MR analysis of IL-13 did not provide evidence for reverse causation (\( \text{Beta}_{[\text{se}]} = -0.05[0.04]; \text{p-value} = 0.25 \)). Neither the heterogeneity nor the pleiotropy tests were significant for IL-13 (\( \text{Q[df]} = 1.37[3], \text{Egger intercept}_{[\text{se}]} = 0.07[0.05]; \text{p-values} = 0.71, \text{and} 0.23, \text{respectively} \)). Furthermore, except for the MR Egger method all other four MR approaches confirmed the observed causal association (Table 1).

The observed causal role of IL-13 in severe COVID-19 was consistently validated and confirmed by all three validation strategies. First, independent replication in an East Asian GWAS of severe COVID-19 returned a significant effect (OR [CI95%] = 6.17 [1.42–26.84]; \( P = 0.01 \)) (Supplementary Fig. 1). Second, internal replication in the GenOMICC study confirmed the observed significant results (OR [CI 95%] = 1.23 [1.01–1.50], \( P = 0.04 \)). Finally, also replication at transcript level yielded a significant association (OR [CI95%] = 1.27 [1.15–1.41]; \( P = 4.09 \times 10^{-6} \)) (Supplementary Fig. 2).

We also identified 13 nominally significant causal associations for IL-13 against blood levels of other cytokines, of which six passed a Bonferroni threshold of \( P < 0.00125 \) i.e., 0.05/40. These include VEGF, IL12p70, IL10, IL7, IL5, and IFNg (Supplementary Table 3).

In summary, we found an OR of about 1.2 for severe COVID-19 per 1 SD increase in IL-13 levels and validated this finding in three independent datasets. IL-13 has previously been studied in asthma with its contribution to IgE production, histamine release and inflammation, as well as barrier damage in the airways. An important observation supporting its role in severe COVID-19 is provided by a recent study reporting that COVID-19 patients receiving Dupilumab, a monoclonal antibody which blocks IL-13/IL-4 signaling, had less severe disease. Warranting further investigations, a study in SARS-CoV-2-infected mice has shown that IL-13 inhibition leads to reduced hyaluronan expression, a polysaccharide which deposits in lungs of severe COVID-19 patients, as well as reduced mortality and disease severity. Our observation of a positive causal effect of IL-13 on a number of other cytokine levels is in line with a previously described key regulatory role of IL-13 in the cytokine storm of COVID-19 patients, where IL-13 recruits inflammatory cells (such as neutrophils, macrophages, eosinophils, and lymphocytes) to the lung mucosa, leading to hyper-production of various pro-inflammatory cytokines.

Despite successful identification (and consistent independent validation) of a causal relationship for IL-13 on severe COVID-19, our study also suffers from a number of limitations: First, the causal effect of IL-13 on severe COVID-19 did not survive Bonferroni correction (\( P < 0.0038 \) i.e., 0.05/13; with 13 as the number of tested cytokines). This can be due to the limited power of a modest number of suitable genetic instruments available for MR. Second, cytokines without sufficiently strong genetic instruments...
were not included in our MR analyses and therefore, our results do not reject potential causal associations for these cytokines. Third, the majority of study populations for our analyses are of European descent, which limits the generalizability of the results to other ancestries. While we independently replicated our findings using GWAS results of severe COVID-19 in an East Asian population \((n = 203)\), we didn’t have IL-13 GWAS in the same ancestry. Larger efforts using exposure and outcome GWASs from the same/similar populations are needed to unravel trans-ancestry portability of this finding.

To conclude, our study provides evidence for a causal effect of IL-13 on severe COVID-19. As such, further investigation is warranted exploring IL-13 as a potential therapeutic target for patients with severe COVID-19 or for those that are at risk of developing severe symptoms.

**Declaration of Competing Interest**

The authors declare that they have no competing interests.

**Acknowledgement**

ZK and AV are financially supported by the Ministry of Health and Medical Education, Iran.

We thank the COVID-19 Host Genetics Initiative for making GWAS summary statistics publicly available.

**Supplementary materials**

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2022.05.024.

**References**

1. Li Y, Wei L, He L, Sun J, Liu N. Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: a meta-analysis. *J Infect 2022;0(0):825–33* Apr 21.
2. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun 2018;9(1):224* Jan 15.
3. COVID-19 Host Genetics Initiative Mapping the human genetic architecture of COVID-19. *Nature 2021;600(7869):472–7* Dec 16.
4. Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pirkónen N, Lehtimäki T, et al. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genetics 2017;100(1):40–50 Jan.

5. Wu P, Ding L, Li X, Liu S, Cheng F, He Q, et al. Trans-ethnic genome-wide association study of severe COVID-19. Commun Biol 2021;4(1):1034 Aug 31.

6. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martín D, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell 2016;167(5):1398–1414.e24 Nov 17.

7. Morone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol 2019;10:1387.

8. Qi C. Multi-Omics Approaches to Understand Respiratory Disease. University of Groningen; 2021.

9. Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, et al. IL-13 is a driver of COVID-19 severity. JCI Insight 2021;6(15):150107 Aug 9.

10. Deimel LP, Li Z, Ranaisinghe C. Interleukin-13 as a target to alleviate severe coronavirus disease 2019 and restore lung homeostasis. J Clin Transl Res 2021;7(1):116–20 Feb 25.

Zoha Kamali

Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands

Department of Bioinformatics, Isfahan University of Medical Sciences, Isfahan, Iran

Judith M. Vonk, Chris H.L. Thio

Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands

Ahmad Vaez

Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands

Department of Bioinformatics, Isfahan University of Medical Sciences, Isfahan, Iran

Harold Snieder

Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands

*Corresponding author at: Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1 (9713 GZ), PO Box 30.001, Groningen 9700 RB, the Netherlands.

E-mail address: a.vaez@umcg.nl (A. Vaez)